Page last updated: 2024-09-04

cox 189 and Hematochezia

cox 189 has been researched along with Hematochezia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bannwarth, B; Berenbaum, F	1
Baraf, HS	1

Reviews

2 review(s) available for cox 189 and Hematochezia

Article	Year
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Dysmenorrhea; Female; Gastrointestinal Hemorrhage; Humans; Osteoarthritis; Pain, Postoperative; Randomized Controlled Trials as Topic	2005
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Current pharmaceutical design, 2007, Volume: 13, Issue:22 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones	2007

Article

Year

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Dysmenorrhea; Female; Gastrointestinal Hemorrhage; Humans; Osteoarthritis; Pain, Postoperative; Randomized Controlled Trials as Topic

2005

Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.

Current pharmaceutical design, 2007, Volume: 13, Issue:22

Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones

2007